Daily Hot Takes from SOCU 2026: Day 1 Highlights
Day 1 of the 17th Annual Skin of Color Update (SOCU 2026) opened with a historic sense of community, reflection, and relentless dedication to advancing dermatologic care for patients with skin of color.
Co-Chairs Andrew F. Alexis, MD, MPH, FAAD, and Eliot F. Battle, MD, welcomed attendees from across the globe—spanning Europe, the Caribbean, the UK, and across the United States—marking 17 y …
Day 1 of the 17th Annual Skin of Color Update (SOCU 2026) opened with a historic sense of community, reflection, and relentless dedication to advancing dermatologic care for patients with skin of color.
Co-Chairs Andrew F. Alexis, MD, MPH, FAAD, and Eliot F. Battle, MD, welcomed attendees from across the globe—spanning Europe, the Caribbean, the UK, and across the United States—marking 17 y … Continue reading "Daily Hot Takes from SOCU 2026: Day 1 Highlights"
The weight loss benefits of GLP-1 agonists have long been established, yet could these drugs have a secondary anti-inflammatory impact? Steven Daveluy, MD, FAAD, director of the Wayne State Dermatology Residency Program, gives the latest in GLP-1s in the treatment of hidradenitis suppurativa (HS) and psoriasis, in this Next Steps in Derm video interview, conducted in partnership with the ODAC Derm … 
Dermatology clinicians have a plethora of treatment options to consider for their psoriasis patients, from topicals to phototherapy to systemics. Yet there’s a non-prescription, adjunctive strategy that clinicians may hesitate to broach in office visits for psoriasis. Research shows dietary strategies that reduce energy intake, such as a low-calorie diet or intermittent fasting, may reduce psori … 
Children with dermatologic conditions, ranging from eczema to psoriasis to hidradenitis suppurativa, are benefitting from advances in biologic therapy with several FDA-approved treatment options. However, real-life clinical experience reveals biologic therapy is not always initiated when prescribed. In addition, even when biologic therapy is initiated, adherence is often not maintained. Therefore, … 
What is the first-line therapy for the mild-moderate disease depicted in the image?
A. Narrow-band UVB
B. Biologic agents
C. Acitretin
D. Topical glucocorticoids
E. Methotrexate
To find out the correct answer and read the explanation, click here.
Brought to you by our brand partner
*Brand partners had no involvement in the content of the questions or answers. …